Arch Pharmalabs Limited Eyes $100M by 2010 from DSM Deal

MUMBAI, Dec 4 (Reuters) - India’s Arch Pharma Labs expects to get at least $100 million by 2010 from the bulk drug manufacture deal it has entered with Dutch chemicals group DSM (DSMN.AS: Quote, Profile, Research), a top official said on Tuesday.

MORE ON THIS TOPIC